TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two deaths involving counterfeit versions of investigational weight-loss drug retatrutide were reported to the FDA, according to a MedPage Today roundup citing CBS News. The report does not establish that retatrutide itself caused either death, and it gives no details about the products or cases. Separately, Novo Nordisk plans to discontinue the weight-loss injection Saxenda in early 2027 because of declining sales.
Two deaths involving counterfeit versions of retatrutide, an investigational weight-loss drug, were reported to the U.S. Food and Drug Administration, according to an October 13 MedPage Today roundup citing CBS News. The report does not establish that retatrutide caused the deaths; the cases involve products described as counterfeit, and further details were not provided.
Retatrutide remains investigational, and the source material does not say that it is approved for general use. The reported deaths concern counterfeit versions of the drug, not confirmed use of a regulated, approved retatrutide product. The FDA received reports, but the roundup does not identify the people who died, when the deaths occurred, where the products were obtained, or what substances they contained.
The roundup also noted that lawsuits allege severe adverse events associated with GLP-1 receptor agonists, citing NPR. Those are allegations in ongoing litigation, not findings established by the short report. Retatrutide is investigational, and the source does not provide evidence connecting the reported counterfeit-product deaths to the broader lawsuits.
In a separate development, Novo Nordisk plans to discontinue Saxenda, its liraglutide weight-loss injection, in early 2027 because of declining sales, according to the roundup. It did not specify a final sales date, whether availability will differ by market, or what support will be offered to patients currently using the medicine.
Counterfeit Products Raise Safety Concerns
The reported deaths underscore the potential danger of products marketed as prescription or investigational medicines when their identity and contents are not verified. A counterfeit product may not match the drug it claims to contain; the roundup does not report laboratory testing or establish what was in the products involved. That uncertainty makes it unsafe to infer that retatrutide itself caused the deaths.
The report also puts two different issues into view: alleged harms involving GLP-1 medicines and a planned commercial discontinuation. Claims in lawsuits are not proof of causation, and Saxenda’s planned withdrawal is attributed to declining sales, not to a safety action. Readers should not treat these developments as evidence that all weight-loss medicines share the same risks or status.
For people considering weight-loss treatment, the distinction between an approved medicine and an investigational drug matters. Retatrutide is described here as investigational; the roundup offers no basis for treating products sold outside regulated channels as equivalent to a medicine studied in clinical trials. People using Saxenda may also need information from their prescriber and Novo Nordisk as the planned 2027 discontinuation approaches.
GLP-1 receptor agonist weight loss injections
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Separate Drug Developments in the Report
The source is a brief October 13, 2026 MedPage Today roundup of developments across endocrinology. It groups the counterfeit-retatrutide death reports with other news, including lawsuits over alleged GLP-1-related adverse events and the planned Saxenda discontinuation. The source provides only short summaries, so it does not supply full case records, regulatory documents, or detailed company statements.
The roundup also described other developments that help show the breadth of the coverage, not evidence about the deaths. The World Health Organization announced obesity guidelines for children and adolescents that recommend against weight-loss drugs or bariatric surgery for children younger than 10, according to the report. Zealand Pharma reported results for investigational petrelintide in a phase II trial, while oral semaglutide prescriptions for weight management reportedly passed 100,000 within two months of approval.
These items concern different medicines, populations, and types of evidence. Trial findings, prescribing figures, lawsuits, and reports of deaths involving counterfeit products cannot be combined into a single conclusion about the safety or effectiveness of weight-loss treatments.
“Two recent deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication, were reported to the FDA.”
— MedPage Today, citing CBS News
Details Behind the Death Reports
The available report does not identify the people who died, the dates or locations of the cases, or how the products were obtained. It also gives no information about the products’ ingredients, testing, or possible contaminants, and does not describe other substances or medical circumstances that may have been involved.
It is not clear what the FDA has concluded, whether it has issued a public alert, or whether the reports have been independently verified. A report submitted to the agency is not, by itself, proof that a particular product caused a death. The source likewise does not say that either death involved a legally supplied product or a clinical trial.
For Saxenda, the roundup does not provide the specific discontinuation date, geographic scope, or arrangements for current users. The stated reason is declining sales, but further details about availability and company guidance were not included.
FDA and Saxenda Updates
The next useful information would be FDA clarification about the counterfeit-product reports, including whether the agency has identified the products, tested samples, or issued safety guidance. Until more information is available, the source supports reporting the deaths as cases involving counterfeit versions of an investigational drug, not as established deaths caused by retatrutide.
Novo Nordisk’s announced plan points to a Saxenda discontinuation in early 2027. The company’s further guidance, including timing and availability by market, will determine what current users need to know. People using the medicine should seek individualized advice from their healthcare professional rather than stopping or changing treatment based solely on a brief news roundup.
Further reporting may also clarify the status of the lawsuits cited in the roundup. Their allegations should remain distinguished from regulatory findings, clinical-trial evidence, and confirmed causes of harm.
Key Questions
Did the report prove retatrutide caused two deaths?
No. It says two deaths involving counterfeit retatrutide versions were reported to the FDA. It does not establish what caused the deaths or whether the products contained retatrutide.
Is retatrutide an approved weight-loss drug?
The source describes retatrutide as investigational. It does not report that the drug has been approved for general use.
Why is Novo Nordisk discontinuing Saxenda?
The MedPage Today roundup says Novo Nordisk plans to discontinue the liraglutide injection in early 2027 because of declining sales. It does not describe the decision as a safety withdrawal.
When will Saxenda become unavailable?
The report gives early 2027 as the planned discontinuation period but does not specify an exact date or explain whether timing will vary by country.
What should current Saxenda users do?
The report does not provide individual treatment advice. People currently using Saxenda should ask their prescriber about their care and watch for further information from Novo Nordisk on timing and availability.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
